PRTA Prothena Corp Public Ltd Co

Price (delayed)

$26.72

Market cap

$1.25B

P/E Ratio

18.69

Dividend/share

N/A

EPS

$1.43

Enterprise value

$718.55M

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating ...

Highlights
The net income has soared by 154% YoY
Prothena's debt has decreased by 34% YoY and by 12% from the previous quarter
The company's EPS has surged by 146% YoY but it fell by 5% QoQ
The company's equity has surged by 87% YoY but it fell by 6% QoQ
The quick ratio has declined by 14% since the previous quarter

Key stats

What are the main financial stats of PRTA
Market
Shares outstanding
46.81M
Market cap
$1.25B
Enterprise value
$718.55M
Valuations
Price to earnings (P/E)
18.69
Price to book (P/B)
2.84
Price to sales (P/S)
6.19
EV/EBIT
10.88
EV/EBITDA
9.87
EV/Sales
3.56
Earnings
Revenue
$201.57M
EBIT
$66.04M
EBITDA
$72.78M
Free cash flow
$88.31M
Per share
EPS
$1.43
Free cash flow per share
$1.89
Book value per share
$9.4
Revenue per share
$4.32
TBVPS
$12.45
Balance sheet
Total assets
$581.41M
Total liabilities
$142.53M
Debt
$10.88M
Equity
$438.89M
Working capital
$519.12M
Liquidity
Debt to equity
0.02
Current ratio
15.22
Quick ratio
14.88
Net debt/EBITDA
-7.31
Margins
EBITDA margin
36.1%
Gross margin
100%
Net margin
33.4%
Operating margin
32.8%
Efficiency
Return on assets
11.9%
Return on equity
16%
Return on invested capital
722.6%
Return on capital employed
12.1%
Return on sales
32.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRTA stock price

How has the Prothena stock price performed over time
Intraday
-0.19%
1 week
3.01%
1 month
-5.21%
1 year
-44.92%
YTD
-45.91%
QTD
-26.93%

Financial performance

How have Prothena's revenue and profit performed over time
Revenue
$201.57M
Gross profit
$201.57M
Operating income
$66.14M
Net income
$67.42M
Gross margin
100%
Net margin
33.4%
Prothena's operating income has surged by 155% YoY but it has decreased by 8% QoQ
The net income has soared by 154% YoY
The operating margin has soared by 100% year-on-year but it is down by 9% since the previous quarter
Prothena's net margin has soared by 100% YoY

Growth

What is Prothena's growth rate over time

Valuation

What is Prothena stock price valuation
P/E
18.69
P/B
2.84
P/S
6.19
EV/EBIT
10.88
EV/EBITDA
9.87
EV/Sales
3.56
The company's EPS has surged by 146% YoY but it fell by 5% QoQ
The company's equity has surged by 87% YoY but it fell by 6% QoQ
PRTA's price to book (P/B) is 51% lower than its last 4 quarters average of 5.8 and 11% lower than its 5-year quarterly average of 3.2
PRTA's price to sales (P/S) is 98% lower than its 5-year quarterly average of 374.1 and 66% lower than its last 4 quarters average of 18.3

Efficiency

How efficient is Prothena business performance
Prothena's return on assets has surged by 135% YoY but it has decreased by 8% QoQ
The ROE has soared by 128% YoY but it has decreased by 12% from the previous quarter
The company's return on sales has surged by 100% YoY but it fell by 9% QoQ
The ROIC has grown by 31% from the previous quarter

Dividends

What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTA.

Financial health

How did Prothena financials performed over time
The total assets has soared by 53% YoY but it has decreased by 4.6% from the previous quarter
The quick ratio has declined by 14% since the previous quarter
Prothena's debt is 98% less than its equity
The company's equity has surged by 87% YoY but it fell by 6% QoQ
Prothena's debt to equity has shrunk by 71% YoY and by 33% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.